drugset / Trial / NCT00987753
Study Evaluating the Safety and Tolerability of L-377202
Phase 1/2
Completed
13 enrolled
University of Alabama at Birmingham
Merck Sharp & Dohme LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to (1) determine the maximally tolerated dose (MTD) of L-377202 administered once every 3 weeks, (2) evaluate the safety and tolerability of L-377202 including the dose-limiting adverse effects of treatment with L-377202, and (3) assess the pharmacokinetics of various doses of L-377202 and the plasma profile of liberated doxorubicin and leu-doxorubicin.
Timeline
- Start
- 1999-03
- Primary completion
- 2000-09
- Completion
- 2001-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L-377202 | Small molecule | 20 mg/m2 | — |